[HTML][HTML] Treatment of lung infection in patients with cystic fibrosis: current and future strategies
In patients with cystic fibrosis (CF) lung damage secondary to chronic infection is the main
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …
cause of death. Treatment of lung disease to reduce the impact of infection, inflammation …
Socio-economic burden of rare diseases: a systematic review of cost of illness evidence
Cost-of-illness studies, the systematic quantification of the economic burden of diseases on
the individual and on society, help illustrate direct budgetary consequences of diseases in …
the individual and on society, help illustrate direct budgetary consequences of diseases in …
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
SCL Hewer, S Smith, NJ Rowbotham… - Cochrane Database …, 2023 - cochranelibrary.com
Background Respiratory tract infections with Pseudomonas aeruginosa occur in most
people with cystic fibrosis (CF). Established chronic P aeruginosa infection is virtually …
people with cystic fibrosis (CF). Established chronic P aeruginosa infection is virtually …
Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis
S Smith, NJ Rowbotham - Cochrane Database of Systematic …, 2022 - cochranelibrary.com
Background Inhaled antibiotics are commonly used to treat persistent airway infection with
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …
Pseudomonas aeruginosa that contributes to lung damage in people with cystic fibrosis …
Inhaled Tobramycin (TOBI®) A Review of its Use in the Management of Pseudomonas aeruginosa Infections in Patients with Cystic Fibrosis
SM Cheer, J Waugh, S Noble - Drugs, 2003 - Springer
Specifically formulated for nebulisation using the PARI LC PLUS™ reusable nebuliser,
tobramycin solution for inhalation (TSI)[TOBI®] provides a high dose of tobramycin (an …
tobramycin solution for inhalation (TSI)[TOBI®] provides a high dose of tobramycin (an …
Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another
Background: Geographic transferability of economic evaluation data from one country to
another has the potential to make a more efficient use of national and international …
another has the potential to make a more efficient use of national and international …
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
S Smith, NJ Rowbotham… - Cochrane Database of …, 2022 - cochranelibrary.com
Background Cystic fibrosis is a genetic disorder in which abnormal mucus in the lungs is
associated with susceptibility to persistent infection. Pulmonary exacerbations are when …
associated with susceptibility to persistent infection. Pulmonary exacerbations are when …
Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis
J Lam, S Vaughan, MD Parkins - Clinical Medicine Insights …, 2013 - journals.sagepub.com
Repeated bouts of acute and chronic lung infections are responsible for progressive
pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to …
pulmonary function decline in individuals with cystic fibrosis (CF), ultimately leading to …
Tobramycin for inhalation in cystic fibrosis: Beyond respiratory improvements
A Chuchalin, E Amelina, F Bianco - Pulmonary pharmacology & …, 2009 - Elsevier
European consensus guidelines recommend nebulised antibiotics for maintenance therapy
in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two …
in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection. Two …
Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature
JR Weiner, EL Toy, P Sacco, MS Duh - Expert opinion on …, 2008 - Taylor & Francis
Background: Cystic fibrosis is the most common incurable hereditary disease in the US.
Persistent respiratory infection is the leading cause of morbidity and mortality in cystic …
Persistent respiratory infection is the leading cause of morbidity and mortality in cystic …